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ABSTRACT  
Structure-based drug design (SBDD) and ligand-based drug design (LBDD) are the two basic approaches of computer-aided drug design (CADD) 
used in modern drug discovery and development programme. Virtual screening (or in silico screening) has been used in drug discovery 
program as a complementary tool to high throughput screening (HTS) to identify bioactive compounds. It is a preliminary tool of CADD that has 
gained considerable interest in the pharmaceutical research as a productive and cost-effective technology in search for novel molecules of 
medicinal interest. Docking is also used for virtual screening of new ligands on the basis of biological structures for identification of hits an d 
generation of leads or optimization (potency/ property) of leads in drug discovery program. Hence, docking is approach of SBDD which plays 
an important role in rational designing of new drug molecules. Quantitative structure-activity relationship (QSAR) is an important chemometric 
tool in computational drug design. It is a common practice of LBDD. The study of QSAR gives information related to structural  features and/or 
physicochemical properties of structurally similar molecules to their biological activity. In this paper, a comprehensive review on several 
computational tools of SBDD and LBDD such as virtual screening, molecular docking and QSAR methods of and their applications in the drug 
discovery and development programme have been summarized. 
Keywords: Virtual screening, Molecular docking, QSAR, Drug discovery, Lead molecule 
 
Article Info: Received 29 April 2020;     Review Completed 16 June 2020;     Accepted 27 June 2020;     Available online 15 July 2020 
Cite this article as: 
Rudrapal M, Chetia D, Virtual Screening, Molecular Docking and QSAR Studies in Drug Discovery and Development 
Programme, Journal of Drug Delivery and Therapeutics. 2020; 10(4):225-233       
http://dx.doi.org/10.22270/jddt.v10i4.4218                                                                                                                  
*Address for Correspondence:  
Mithun Rudrapal, Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India 
 
 
INTRODUCTION 
Drug-like properties are defined as molecule’s intrinsic 
properties that remain an integral element in drug discovery 
research. The physicochemical properties of a drug molecule 
have an important impact on its pharmacokinetic (PK), 
metabolic fate and toxicity in the body, and so a good 
understanding of these properties, coupled with their 
prediction, are crucial for a successful drug discovery 
programme1. Virtual screening is a predictive in silico high 
throughput screening (HTS) tool used in computer-aided 
drug design (CADD) which evaluates the drug-likeness 
(including ADME-Tox and toxicity properties) of ligands/ 
molecules that have potential problems related to PK and 
toxicities, independent of their intended drug target. 
Physicochemical properties that affect the PK and toxicity of 
drug molecules are required to be constantly re-evaluated 
(or optimized) in order to bring success in drug discovery by 
enhancing speed, efficiency and quality of research2-4. 
Inefficient research, attrition, and costs are reduced if 
compounds have good drug-like properties. The assessment 
of drug-likeness, ADME-Tox properties and toxicity 
parameters are, therefore, important aspects in the 
development of good clinical candidates that have a balance 
of activity and molecular properties. A drug lead molecule 
with desired drug-like properties can be transformed into 
quality drug candidate5,6. Further, Good activity and drug-
like properties are complementary, and both are necessary 
even for a good drug product. A less potent compound with 
better properties may produce a better therapeutic response 
and thus be a better drug candidate7. Molecular docking is a 
computational tool used extensively in Structure-Based Drug 
Design (SBDD) for the determination of binding affinity and 
relative orientation between a protein and a ligand when 
they are bound to each other. This technique simulates the 
process of molecular recognition by predicting the binding 
free energy as well as interaction geometry of a bound 
protein-ligand complex. Docking thus predicts the preferred 
orientation (i.e., ‘best fit’ orientation in 3D space) of a ligand 
that binds to a particular protein of interest. Structure-
Activity Relationship (SAR) is the study of relationship 
between the chemical or structural properties of a molecule 
and its biological activity. The analysis of SAR determines the 
chemical groups responsible for evoking the biological 
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response a drug molecule. This is a common practice of 
medicinal chemistry which allows modification of the effect 
(i.e., activity) of a bioactive compound (or drug molecule) by 
changing its chemical structure. 
VIRTUAL SCREENING AND DRUG-LIKENESS 
Drug-likeness 
Virtual screening (or in silico screening) has been used in 
drug discovery program as a complementary tool to high 
throughput screening (HTS) to identify bioactive compounds. 
It is a new approach of Computer-Aided Drug Design (CADD) 
that has gained considerable interest in the pharmaceutical 
research as a productive and cost-effective technology in the 
search for novel molecules of medicinal interest. Apart from 
physical HTS, virtual screening refers to a range of in silico 
techniques that perform computational screening of large 
libraries of chemical compounds (chemical 
databases/compound collections) to identify a smaller 
number of possible bioactive compounds in order to 
prioritize them for synthesis or biological assay. The virtual 
screening is done mainly by two methods, one is on the basis 
of known biological structures (structure-based screening or 
docking) or the other is by means of molecular similarity 
analyses using active compounds as templates (ligand-based 
screening). However, the purpose of virtual screening is, 
therefore, the reduction of a huge virtual chemical space (of 
small organic molecules), to synthesize and/or test against a 
specific target protein, to a relatively smaller number of 
compounds that have a good chance to lead to a drug 
candidate. Virtual screening of compound libraries has 
recently gained significant interest to early identification of 
drug leads in drug discovery programs.  
Many drug candidates fail at the pre-clinical and clinical 
stages of development due to their lack of efficacy and/or 
due to the reasons unrelated to the efficacy against intended 
drug target. Failure of drug molecules due to the lack of 
optimal drug-like properties is dominating. Pharmacokinetic 
(PK) and toxicity issues are accounted for more than half of 
the failure in the clinical trials. It results in increased time 
and costs per new drug product development. Therefore, 
preliminary study of virtual screening evaluates the drug-
likeness (including ADME-Tox and toxicity properties) of the 
ligands/molecules that have potential problems related to 
PK and toxicities, independent of their intended drug target. 
In later stage, screening of drug-like molecules is done by 
molecular docking method based on the structure of 
intended drug target. Molecules (ligands) predicted to bind 
well with the compliment target molecule are selected for 
the further experimental study1-4.  
Drug-likeness screening predicts the likelihood that a 
molecule has desired drug-like characteristics and 
physicochemical properties, called drug-like properties. 
Drug-like properties are defined as molecule’s intrinsic 
properties that remain an integral element in drug discovery 
research. The physicochemical properties of a drug molecule 
have an important impact on its PK, metabolic fate and 
toxicity in the body, and so a good understanding of these 
properties, coupled with their prediction, are crucial for a 
successful drug discovery programme5,6. A list of the drug-
like properties of interest is presented in Table 1. 
  
Table 1: Drug-like properties6 
Structural Physicochemical Biochemical PK and Toxicity 
Lipophilicity (LogP) Solubility Metabolism (Phases I and II) Bioavailability 
Dissociation constant (pKa) Permeability Protein and tissue binding Half-life 
Molecular weight (MW) Chemical stability Transport (uptake, efflux) Clearance 
H-bonding  Target affinity Drug-drug interaction 
Polar surface area (PSA) LD50 
 
Drug-likeness screening basically performs calculation of 
fundamental molecular properties and Lipinski’s parameters 
along with other physicochemical properties, which assesses 
the acceptability of compounds as drug-like molecules. They 
represent the combined physicochemical, PK and 
pharmacodynamic (PD) properties (collectively termed as 
drug-like properties) of molecules to exhibit good drug-
likeness behavior in human body. In fact, molecular 
properties are the fundamental structural parameters that 
determine the physicochemical and biochemical properties, 
which ultimately determine molecule’s pharmacokinetics, 
toxicity and pharmacodynamics (affinity and efficacy) 
properties7,8 (Figure 1).  
According to Lipinski’s rule of five (1997), compounds are 
more likely to be drug-like and orally bioavailable if they 
obey the following criteria: LogPo/w (octanol/water partition 
coefficient) ≤ 5, MW (molecular weight) ≤ 500, HBAs 
(hydrogen bond acceptors) ≤10 and HBD (hydrogen bond 
donors) ≤ 5. To further substantiate Verber et al. stated that 
compounds with ≤10 RotB (rotable bonds) and TPSA (total 
polar surface area) of ≤140 A2 are more likely to show 
membrane permeability and good bioavailability. 
Structural properties
Physicochemical properties Biochemical properties
Pharmacokinetics and Toxicity
Pharmacodynamics 
(Efficacy and Safety)
Physical Biological
Leads
Biological 
target
Drug-receptor
interaction
Hits
(Ligands)
Drug
Figure 1: Drug-like properties and their role in various 
phases of drug action 
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Poor absorption or permeation is more likely when the MW 
is over 500, the calculated logP (clogP) is higher than 5, 
when there are more than 10 HBAs (expressed as sum of Ns 
and Os), more than 5 HBDs (expressed as sum of OHs and 
NHs) and greater than 140 A2 molecular TPSA (due to polar 
atoms, N and O plus attached hydrogens)7-9. Typical ranges 
of properties related to drug-likeness are depicted in Table 
2. Lipinski’s rule of five is considered predictive guideline for 
oral bioavailability; however, 16% of oral drugs violate at 
least one of the criteria and 6% fail in two or more. About 
70% of drug-like molecules have between 2 and 9 HBAs, 0 
and 2 HBDs and between 2 and 8 RotB. Lipinski’s rule is 
therefore used as a filter to decrease the library size before 
docking or to eliminate some ligands before synthesis in the 
design of new drug molecules or optimization of drug 
leads9,10. 
Table 2: Typical ranges of properties related to drug-
likeness9 
Parameter Minimum Maximum 
LogP  -2 5  
MW 200 500 
HBAs 0 10 
HBDs 0 5 
TPSA 0 140 
RotB 0 8 
 
ADME-Tox prediction 
ADME-Tox (Absorption, Distribution, Metabolism, Excretion 
and Toxicity) properties have a predictable influence on PK, 
metabolic fate and PD effects of drug molecules. A majority 
of candidate drugs fail at the pre-clinical stage of drug 
development which increases the costs of per new drug 
development. It has been reported that about 63% the 
candidate drugs fail due to their poor or unsatisfactory 
ADME-Tox properties. The calculation of ADME-Tox 
properties is therefore intended as the first step towards 
optimizing new drug molecules, whether to check the failure 
of lead molecules which may cause toxicity and are unable to 
cross the intestinal membranes or metabolized by the body 
into an inactive form. The prediction of ADME-Tox 
properties reduce failure rate of compounds in late stage of 
drug discovery. It focuses on predictions of chemical 
modifications of compounds that will likely improve PK and 
PD properties.  
The optimal approach for performing the ADME-Tox 
prediction is one that uses both in vitro and in silico studies 
in a complementary way ensuring that ADME-Tox is 
considered at almost every stage of the drug discovery 
process, from hit identification to lead optimization. In the 
hit identification stage, the goal of the in silico ADME-Tox 
prediction is to identify compounds with acceptable drug-
like properties. In the lead identification stage, the objective 
is to identify a small number of compounds with the activity, 
selectivity and drug-like properties required for a potential 
drug candidate. In vitro assays are used to measure the 
ADME-Tox properties of the newly synthesized compounds. 
However, this information is valuable for the refinement of 
the in silico ADME-Tox models (Table 3). There are two key 
aims of ADME-Tox prediction: first, to design new 
compounds and compound libraries so as to reduce the risk 
of attrition at late stage; and second, to optimize the 
screening and testing prioritizing only the most promising 
compounds11-13. The ADMET properties that can be 
evaluated using in silico models are intestinal permeability, 
aqueous solubility, lipophilicity, human oral bioavailability, 
blood-brain barrier permeation, plasma protein binding, 
metabolic stability, interactions with cytochrome P450s and 
hepatotoxicity.
 
Table 3: Prediction of ADME-Tox properties at various stages of drug discovery3 
Hit identification Lead identification Lead optimization 
Identify compounds or series 
with acceptable drug-like 
properties 
Prediction of chemical 
modification that improves the 
ADME-Tox properties 
Similar to the process of lead identification 
Refinement of compounds using 
experimental data 
 
 
The prediction of ADMET properties estimates the following 
requirements for a drug that  
 must bind tightly to the biological target in vivo 
 must pass through one or more physiological barriers 
(cell membrane or blood-brain barrier) 
 must remain long enough to produce the effect 
 must be removed from the body by metabolism, 
excretion, or other means13,14 
Toxicity prediction 
The prediction of toxicity parameters are used for early 
identification of potential problems related to toxicity of 
drug-like molecules. In silico toxicity parameters include 
rodent toxicity, rodent carcinogenicity, skin sensitivity, 
Ames mutagenicity and so on9,15. 
Significance of drug-likeness screening 
The structural and physicochemical properties that affect 
the PK and toxicity of drug molecules are required to be 
constantly reevaluated (or optimized) in order to bring 
success in drug discovery by enhancing speed, efficiency, 
and quality of research. Inefficient research, attrition, and 
costs are reduced if compounds have good drug-like 
properties. The assessment of drug-likeness, ADME-Tox 
properties and toxicity parameters are therefore important 
aspects in the development of good clinical candidates that 
have a balance of activity and molecular properties. A drug 
lead molecule with desired drug-like properties can be 
transformed into quality drug candidate (Figure 2)
. 
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Figure 2: Pyramid of virtual screening  
 
Thus, in virtual screening, lead identification and lead 
optimization consist of an iterative process, starting from in 
silico prediction, chemical synthesis to experimental testing 
and confirmation6,16.  
Good activity and drug-like properties are complementary, 
and both are necessary even for a good drug product. The 
most active or selective compound may not make the best 
drug product because of property limitations that cause 
poor PK or safety profile. A less potent compound with 
better properties may produce a better therapeutic response 
and thus be a better drug candidate (Figure 3)17-21. 
Property
Activity
Activity optimization
(Good drugs)
(Good ligands)
 
Figure 3: Property-activity relationship 
MOLECULAR DOCKING  
Molecular docking is a computational tool used extensively 
in Structure-Based Drug Design (SBDD) for the 
determination of binding affinity and relative orientation 
between a protein and a ligand when they are bound to each 
other. This technique simulates the process of molecular 
recognition by predicting the binding free energy as well as 
interaction geometry of a bound protein-ligand complex. 
Docking thus predicts the preferred orientation (i.e., ‘best fit’ 
orientation in 3D space) of a ligand that binds to a particular 
protein of interest. The aim of molecular docking is to 
achieve an energetically favorable conformation for both the 
protein and ligand such that the ligand molecule undergoes 
optimal interaction with the binding site of protein (or 
receptor) molecule to obtain a stable protein-ligand 
complex22,23. 
Docking components 
The molecular docking is divided into two main components, 
viz., search algorithm and scoring function. 
Search algorithm determines all possible optimal 
conformations for a given protein-ligand complex i.e., the 
position and orientation of both molecules relative to each 
other. They also calculate the energy of the resulting 
complex and of each individual interaction. More clearly, a 
search algorithm generates ‘poses’ i.e., orientations of 
particular conformations of the ligand in the active (binding) 
site of protein molecule. It is followed by finding the best 
conformation of the ligand appropriate for optimal 
interaction with the protein structure which is measured by 
scoring function. The different types of algorithms that can 
be used for docking searches are molecular dynamics, Monte 
Carlo methods, genetic algorithms and fragment-based 
methods22-25.  
Scoring function is a mathematical method used to predict 
the strength of intermolecular interaction (non-covalent) 
between protein and ligand after they have been docked. 
The prediction of the binding free energy (binding affinity) is 
called scoring. A molecule with a good docking score is 
potentially a good binder. The scoring function assigns a 
priority order to a set of structurally diverse ligands docked 
to the same protein and estimates binding (or interaction) 
energy. The ligands are ranked according to the interaction 
energy based on scoring functions. There are different types 
of scoring functions, namely, force field-based, empirical-
based, knowledge-based, and consensus scoring. More 
accurate a scoring functions, more expensive it is. Most 
scoring functions are physics-based molecular mechanics 
force fields that estimate the energy of binding interaction of 
ligand molecules. The empirical scoring function of any 
docking program is expressed as follows (Equation 1): 
Fitness = Elec + vdW + H-bond   (1) 
The binding energy refers to that change in free energy of 
the system as depicted below (Equation 2): 
Protein (in water) + Ligand (in water) -----> Protein-
Ligand complex (in water)  (2) 
The free energy of binding is calculated as the sum of the 
electrostatic energy (due to ionic interaction, Gelect), van 
der Waals energy (GvdW), solvation effects (due to H-
bonding, Gsol) and internal energy changes due to 
conformational (Gconf), rotational (Grot) and torsional 
(Gtor) energies. It is represented as ΔG bind (kcalmol-1) and 
is calculated as follows (Equation 3): 
ΔG bind = ΔGelect + ΔGvdW + ΔGsol + ΔGconf + ΔGrot + Gtor     (3) 
Compound library or Database 
Virtual screening  
(Drug-likeness, Docking) 
Hits 
ADME-Tox 
Toxicity 
Leads 
Synthesis 
Screen 
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The ΔG bind value has to be low for a structure to be stable. 
A low (negative) binding energy indicates a stable complex 
and thus a more likely binding interaction22,24,25.  
Assessment of docking  
The results of docking are analyzed by a statistical scoring 
function which converts interacting energy into numerical 
values, called the docking score. The 3D pose (binding 
mode) of the docked ligand can be visualized using different 
visualizing tools like Chimera, Pymol, Rasmol etc. which 
could help in to identify the best fit orientation of ligand 
considering both docking score (or binding energy) and 
various non-covalent interactions. Docking methods are 
usually assessed by their ability to reproduce the binding 
mode of experimentally resolved protein-ligand complexes. 
The ligand is removed from the complex, a search area is 
defined around the actual binding site, the ligand is 
redocked into the protein, and the binding mode generated 
is compared with the experimental positions usually in 
terms of a root mean square deviation (RMSD). RMSD refers 
to the distance between the initial and final position of the 
ligand in the binding cavity of protein molecule. RMSD has 
often been used to measure the quality of reproduction of a 
known (i.e., crystallographic complex) binding pose by a 
docking method. Lower the value of RMSD, higher is the 
accuracy of docking. If the docking protocol is able to 
produce similar docking pose of a ligand with respect to the 
biological configuration of the same ligand in the crystal 
structure of complex protein then it means that the docking 
method is validated. If the RMSD is below 2 Å, it is generally 
considered a successful prediction. This represents good 
reproduction of the correct pose (or true binding pose)26-30.  
Docking methodology 
Molecular docking studies are usually performed on free like 
AutoDock (Art Olsen, David Goodsell, Scripps), and 
commercial software packages such as Discovery Studio 
(Accelrys), Glide (Schrodinger), GOLD (CCDC) and FlexX 
(BiosolveIT). The crystal structures of protein molecules of 
interest are retrieved from the RCSB Protein Data Bank 
(https://www.rcsb.org)31, 32. The methodology involved in 
molecular docking is depicted in Figure 4. 
Applications of docking 
Docking has two important roles: the search for the 
conformation and configuration of the ligand in the binding 
site, which rank poses for a given small molecule on a given 
target (docking), and the evaluation of the interaction 
energy between the target and ligand, which rank different 
ligands according to their relative affinity for a given target 
(compounds selection). Molecular docking studies are thus 
frequently used to predict the binding orientation (or 
binding mode/pose) of small molecules to their protein 
targets (or receptor) in order to predict the affinity and 
activity of the small molecules. A binding interaction 
between a small molecule ligand and an enzyme protein may 
result in activation or inhibition of the protein. If the protein 
is a receptor, ligand binding may result in agonistic or 
antagonistic effect22,24,33-36.  
 
Small molecule Target molecule
Ligand library Protein
Drug-likeness filter, 
ADMET, Toxicity screen
Preparation
 
Binding site identification, 
Reeptor grid generation
Preparation
Molecular docking
Docking
Scoring
Post-process
Reranking (solvation corretion)
Consensus (inadequecy of single scoring)
Validation (Redocking & superimposition)
Evaluation (Functional geometry & shape complementarity)
Compound selection
In vitro assays
Experimental 
screening
 
Figure 4: Methodology of molecular docking 
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Predicting the mode of protein-ligand interaction can assume 
the active site of the protein or receptor molecule, and 
further help in protein annotation. Docking is also used for 
virtual screening of new ligands on the basis of biological 
structures for identification of hits and generation of leads or 
optimization (potency/property) of leads in drug discovery 
program. Hence, docking plays an important role in rational 
design of new drug molecules37-41.  
STRUCTURE-ACTIVITY RELATIONSHIP (SAR) AND 
QUANTITATIVE STRUCTURE-ACTIVITY 
RELATIONSHIP (QSAR) STUDIES 
SAR/SPR 
Structure-Activity Relationship (SAR) is the study of 
relationship between the chemical or structural properties of 
a molecule and its biological activity. The analysis of SAR 
determines the chemical groups responsible for evoking the 
biological response a drug molecule. This is a common 
practice of medicinal chemistry which allows modification of 
the effect (i.e., activity) of a bioactive compound (or drug 
molecule) by changing its chemical structure. Medicinal 
chemists use the techniques of chemical synthesis and 
computational drug design to insert new chemical 
groups/change existing groups in the bioactive molecule and 
test the modifications for their altered (increased or 
decreased) biological response. The information on SAR is 
obtained from empirical correlation of structural variation 
on the common template (or structural scaffold) of a 
congeneric series of compounds with the experimentally 
determined biological activity. The basic assumption in SAR 
hypothesis is that molecules with similar structures have 
similar activities. This is because of the fact that similar 
compounds may have similar chemical or physicochemical 
properties. Thus, there is a relationship between structure 
and activity of a bioactive molecule, and this is the basis of 
SAR study42.  
The technique of SAR uses molecular properties of bioactive 
compounds to predict biological activity (efficacy, receptor 
binding, toxicity, and bioavailability). The biological effects of 
a new chemical compound can often be predicted from its 
molecular structure using SAR data about other similar 
compounds. Thus, the ability to draw conclusions about the 
biological property of an unknown compound mainly 
depends on the structural features that can be characterized. 
When appropriate judgment is made, SAR can be a powerful 
tool for understanding functional implications when 
structural similarities are found. SAR can be used to develop 
new molecules and optimization of existing compounds (or 
lead molecules) by appropriate assessment of biological 
(therapeutic or toxic) effects43,44.  
Structure-Property Relationship (SPR) defines how structure 
affects properties. This is complementary to SAR. SPR allows 
medicinal chemists to understand how structural 
modifications improve properties for their basic structural 
scaffold. SPR can be developed for a series of structurally 
similar molecules in the same manner as SARs. SAR defines 
how structure modification at one moiety in the molecule 
affects activity, while, SPR defines how structure 
modification affects properties. Medicinal chemists need to 
understand the relationship between chemical structure and 
the physicochemical properties of molecules and how this 
translates into compound’s stability, transport and the 
interaction receptor molecule.  Interaction of drug molecules 
with biological targets implicates the PKs (ADME) and 
toxicities of a compound in biological systems which thereby 
modulate biological function45,46.  
QSAR/QSPR 
The method of SAR can be refined to build mathematical 
relationships between a chemical structure and its biological 
activity, which is known as Quantitative Structure-Activity 
Relationship (QSAR). The fundamental of SAR hypothesis is 
that molecules with similar structures will have similar 
functions (activities), while QSAR hypothesizes that 
biological activity (similar activity) of different molecules can 
be compared quantitatively based on the characteristics of 
their structural components. This study is often referred as 
Quantitative Structure-Activity/Structure-Property/-
Structure-Toxicity Relationship (QSAR/QSPR/QSTR)47-49. 
Principle of QSAR analysis 
QSAR is an important chemometric tool in computational 
drug design. The study of QSAR gives information related to 
structural features and/or physicochemical properties of 
structurally similar molecules to their biological activity. It 
attempts to establish a correlation between the experimental 
activity of a series of compounds and the structural 
information of compounds defined by molecular descriptors. 
QSAR/QSPR models represent mathematical equations 
correlating the response of bioactive compounds 
(activity/property) with their structural and 
physicochemical properties. Similar molecules with minor 
variation in their structures can have quite improved 
biological activities (Figure 5)50,51.  
 
Figure 5: Basis of QSAR study 
This kind of relationship between molecular structure and 
changes in biological activity is the center of focus of QSAR. 
QSAR methods are based upon two basic assumptions, first is 
to derive a quantitative measure from the structural 
properties significant to the biological activity of a 
compound, and the other assumption is to mathematically 
describe the relationship between biological activity to be 
optimized and the molecular property calculated from the 
structure. For a QSAR to be valid and reliable, the activity of 
all of the compounds of a congeneric series covered must be 
elicited by a common biochemical mechanism52. 
Components of QSAR analysis 
The steps involved in QSAR analysis are data set preparation, 
structural optimization, calculation and selection of 
molecular descriptor, correlation model development, and 
finally model evaluation and validation (Figure 6). Good 
QSAR modeling depends on the correct analysis and 
selection of computed descriptors as independent variables 
against biological activity as dependant variable in QSAR 
equations53. 
  
Compounds with 
bio-activity 
New compounds with 
improved bio-activity 
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Figure 6: Steps involved in QSAR analysis 
 
Molecular descriptors are numerical representations of 
chemical information encoded within a molecular structure 
via mathematical procedure. They include constitutional, 
hydrophobic, electronic, steric, geometrical, topological and 
quantum chemical (semi-empirical) properties of molecules. 
Descriptors are used to study the quantitative effects of the 
molecular structure of bioactive compounds on their 
biological activities including inhibitory activities54 (Figure 
7). 
 
 
Figure 7: Relationship between descriptors and biological activity 
 
2D-QSAR  
QSAR models are generally developed with a database of 
specified chemical domain and easily calculable 2D 
molecular descriptors using simple regression-based 
statistical methods such as Multiple Linear Regression 
(MLR) and Partial Least Squares (PLS).  Such quantitative 
relationship between the biological activity of a set of 
compounds and the 2D molecular/structural descriptors of 
compounds is known as 2D-QSAR analysis55. Various 
methods of 2D-QSAR analysis are depicted in Table 4.
  
Table 4: Methods of 2D-QSAR55,56 
Free energy 
models 
Mathematical 
models 
Statistical methods Other methods 
Hansch 
analysis 
(Linear Free 
Energy 
Relationship) 
 
Free Wilson 
analysis 
Fujita-Ban 
modification 
 
Linear Regression Analysis  
-Multiple Linear Regression (MLR) 
-Partial Least Squares (PLS) 
-Discriminant Analysis (DA) 
-Principle Component Analysis (PCA) 
-Principle Component Regression (PCR) 
-Genetic Function Approximation (GFA) 
-Genetic Partial Least Squares (G/PLS) 
Pattern recognition 
-Cluster Analysis (CA) 
-Artificial Neural Network (ANN) 
-k-Nearest Neighbor (kNN) 
Topological methods 
Quantum mechanical methods 
 
The 2D-QSAR analysis describes the activity (response 
property) of a data set and predicts (and/or classifies) 
activities for further sets of untested compounds. After its 
development, a QSAR model is usually verified by employing 
multiple statistical validation tools giving an estimation of its 
statistical quality and predictivity. According to the OECD 
guidelines, the development of a QSAR model should comply 
with unambiguous algorithm strategies and the model 
should pass various testes model fitness, robustness and 
predictivity. A reliable QSAR model once established and 
validated can be useful to predict the activities of molecules, 
and to know which structural features play an important role 
in biological processes57,58.  
Genetic Function Approximation (GFA) algorithm is a new 
artificial intelligence-based method used to build 2D-
QSAR/QSPR/QSTR models. In GFA, the QSAR model is 
obtained by combining both genetic algorithm and statistical 
modelling. GFA is genetic based method which combines 
Holland’s genetic algorithm and Friedman’s Multivariate 
Adaptive Regression Spines (MARS). Application of GFA 
algorithm may construct higher quality predictive models 
and make available additional information not provided by 
standard regression techniques. The GA algorithm can 
handle a huge number of descriptors and generate models 
competitive with or superior to the results of standard 
regression analysis. GFA followed by MLR (GFA-MLR) or 
Chemical  
data base 
Molecular 
modeling and 
optimization 
Descriptor 
generation and 
calculation 
Building QSAR 
model 
Validation of 
QSAR model 
Interpretation 
and application 
Molecular 
descriptor 
Molecular 
properties 
Biological  
activity 
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PLR (G/PLS) regression is frequently used in research for 
the development of predictive QSAR/QSPR models55,58,59,60.  
3D-QSAR  
In recent days, 3D-QSAR have been applied which involve the 
analysis of the quantitative relationship between the 
biological activity of a set of compounds and their three-
dimensional properties using statistical correlation methods. 
3D-QSAR uses probe-based sampling within a molecular 
lattice to determine three-dimensional properties of 
molecules (particularly steric and electrostatic values) and 
can then correlate these 3D descriptors with biological 
activity60,61. Various 3D-QSAR methods in use (on the basis of 
chemometric techniques used) are summarized in Table 5.
 
Table 5: Methods of 3D-QSAR61 
Linear 3D-QSAR Non-linear 3D-QSAR 
-Comparative Molecular Field Analysis (CoMFA) 
-Comparative Molecular Similarity Indices Analysis (COMSIA) 
-Comparative Molecular Movement Analysis (COMMA) 
-Adaptation of Fields for Molecular Comparison (AFMoC)  
-Genetically Evolved Receptor Models (GERM) 
-Self-Organizing Molecular Field Analysis (SoMFA)  
-COMPASS 
-COMFA-PLS (QPLS) 
 
QSAR models help to design new molecules and also 
optimization of lead molecules with improved activity 
profile. QSAR is also an important tool in virtual screening of 
bioactive compounds used to eliminate (compounds lacking 
drug-like properties or compounds predicted to elicit a toxic 
response) from further development in early phase of drug 
discovery and development. It also acts as an informative 
tool by extracting significant patterns in descriptors related 
to the measured biological activity for understanding of 
mechanisms (drug-receptor interactions) of given biological 
response. QSAR has therefore gained significant momentum 
in ligand-based, receptor-based, or other methods of drug 
design62,63. 
CONCLUSION 
In this review, various computational tools of structure-
based/ ligand-based drug design (SBDD/LBDD) including 
virtual screening, molecular docking and QSAR have been 
summarized. Some advanced tools of drug design strategy 
that are widely used in modern drug discovery programme 
include pharmacophore modelling, fragment-based drug 
design and structure similarity search and molecular 
dynamics simulation. These computational tools are 
successfully used in the drug discovery and development 
programme along with bioinformatics and cheminformatics 
tools. In recent days, artificial intelligent technology has also 
been evolved which can successfully be used along with 
omics tools (such as genomics, proteomics, metabolomics 
etc.) and computational biology techniques in modern drug 
discovery and development programme.  
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